Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(6)
•••
Comment by BearDownAZon May 29, 2017 10:51pm
141 Views
Post# 26298595

RE:RE:Removal of videos

RE:RE:Removal of videosAs we've heard before.....these things take time.

I emailed RH suggesting a website update and noting the areas that were way outdated over a year ago. Clearly, website updates take a LONG time. They are simply just catching up with those requests of mine from over a year ago....starting with taking the old stuff down. Don't worry, by 2018 they'll have the new info relevant to today up there. LOL. I'm half joking, but half serious. Legit updates to that website have gone MIA for a long while now. 

When asked in late March about getting a much needed corporate update, RH replied "You'll see a comprehensive update in the weeks to come." Also when RH was asked in late March about what upcoming events Bioasis will be attending/presenting at, RH replied "es we will be announcing events in the coming months …"  

Well.....it's going on 10 weeks now. How many more weeks is it going to be RH....err.....Mark Day.....err whoever.

But you know, these things take time.......

BearDownAZ


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities